404 related articles for article (PubMed ID: 16260852)
1. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer.
Tas F; Duranyildiz D; Argon A; Oğuz H; Camlica H; Yasasever V; Topuz E
Med Oncol; 2005; 22(4):353-8. PubMed ID: 16260852
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer.
Derin D; Soydinç HO; Guney N; Tas F; Camlica H; Duranyildiz D; Yasasever V; Topuz E
Lung Cancer; 2008 Feb; 59(2):240-5. PubMed ID: 17875341
[TBL] [Abstract][Full Text] [Related]
3. The value of serum Bcl-2 levels in advanced lung cancer patients.
Tas F; Duranyildiz D; Oguz H; Camlica H; Oral EN; Yasasever V; Topuz E
Med Oncol; 2005; 22(2):139-43. PubMed ID: 15965276
[TBL] [Abstract][Full Text] [Related]
4. Research on the relationship between serum levels of inflammatory cytokines and non-small cell lung cancer.
Song XY; Zhou SJ; Xiao N; Li YS; Zhen DZ; Su CY; Liu ZD
Asian Pac J Cancer Prev; 2013; 14(8):4765-8. PubMed ID: 24083740
[TBL] [Abstract][Full Text] [Related]
5. Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with treatment response and survival.
Su C; Zhou C; Zhou S; Xu J
Med Oncol; 2011 Dec; 28(4):1453-7. PubMed ID: 20714944
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer.
De Vita F; Orditura M; Auriemma A; Infusino S; Roscigno A; Catalano G
Oncol Rep; 1998; 5(3):649-52. PubMed ID: 9538169
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic value of serum TNF-alpha, IL-10, leptin and CRP levels in newborns with septicemia].
Cesur S; Irmak H; Eras Z; Yaşar H; Sengül A; Dilmen U; Demiröz AP; Biyikli Z; Ilikçi R
Mikrobiyol Bul; 2009 Oct; 43(4):607-12. PubMed ID: 20084913
[TBL] [Abstract][Full Text] [Related]
8. The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma.
Tas F; Oguz H; Argon A; Duranyildiz D; Camlica H; Yasasever V; Topuz E
Med Oncol; 2005; 22(3):241-6. PubMed ID: 16110135
[TBL] [Abstract][Full Text] [Related]
9. Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer.
Ozawa Y; Amano Y; Kanata K; Hasegwa H; Matsui T; Kakutani T; Koyauchi T; Tanahashi M; Niwa H; Yokomura K; Suda T
Med Oncol; 2019 Mar; 36(4):33. PubMed ID: 30825015
[TBL] [Abstract][Full Text] [Related]
10. Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with clinical outcome of erlotinib treatment.
Wang YS; Miao LY; Liu L; Cai HR; Ding JJ; Ren SX; Zhou CC; Schmid-Bindert G
Chin Med J (Engl); 2013 Oct; 126(20):3931-5. PubMed ID: 24157160
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
[TBL] [Abstract][Full Text] [Related]
12. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial.
Krzakowski M; Provencio M; Utracka-Hutka B; Villa E; Codes M; Kuten A; Henke M; Lopez M; Bell D; Biti G; Merimsky O; Beorchia A; Riggi M; Caux NR; Pouget JC; Dubray B; David P
J Thorac Oncol; 2008 Sep; 3(9):994-1002. PubMed ID: 18758302
[TBL] [Abstract][Full Text] [Related]
13. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters.
Mantovani G; Madeddu C; Gramignano G; Lusso MR; Mocci M; Massa E; Ferreli L; Astara G; Macciò A; Serpe R
J Exp Ther Oncol; 2003; 3(4):205-19. PubMed ID: 14567291
[TBL] [Abstract][Full Text] [Related]
15. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy.
Chang CH; Hsiao CF; Yeh YM; Chang GC; Tsai YH; Chen YM; Huang MS; Chen HL; Li YJ; Yang PC; Chen CJ; Hsiung CA; Su WC
Int J Cancer; 2013 May; 132(9):1977-85. PubMed ID: 23034889
[TBL] [Abstract][Full Text] [Related]
16. Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status.
Mantovani G; Macciò A; Madeddu C; Mura L; Gramignano G; Lusso MR; Mulas C; Mudu MC; Murgia V; Camboni P; Massa E; Ferreli L; Contu P; Rinaldi A; Sanjust E; Atzei D; Elsener B
Int J Cancer; 2002 Mar; 98(1):84-91. PubMed ID: 11857390
[TBL] [Abstract][Full Text] [Related]
17. Extracellular cytochrome c as a biomarker for monitoring therapeutic efficacy and prognosis of non-small cell lung cancer patients.
Javid J; Mir R; Julka PK; Ray PC; Saxena A
Tumour Biol; 2015 Jun; 36(6):4253-60. PubMed ID: 25578497
[TBL] [Abstract][Full Text] [Related]
18. Serum concentrations of proinflammatory cytokines in advanced non small cell lung cancer patients.
De Vita F; Orditura M; Auriemma A; Infusino S; Catalano G
J Exp Clin Cancer Res; 1998 Dec; 17(4):413-7. PubMed ID: 10089060
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy.
Mantovani G; Macciò A; Madeddu C; Mulas C; Massa E; Astara G; Ferreli L; Mudu MC; Gramignano G; Murgia V; Lusso MR; Mocci M; Cardia A; Mura L
Oncol Rep; 2002; 9(4):887-96. PubMed ID: 12066227
[TBL] [Abstract][Full Text] [Related]
20. Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival.
Orditura M; Romano C; De Vita F; Galizia G; Lieto E; Infusino S; De Cataldis G; Catalano G
Cancer Immunol Immunother; 2000 Dec; 49(10):530-6. PubMed ID: 11129323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]